Evidence map›Paper›PMID 31187401›Full record

ArticleInfection2019

Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.

Andreas F Widmer, Winfried V Kern, Jan A Roth, Markus Dettenkofer, Tim Goetting, Hartmut Bertz, Christian Theilacker, Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS)

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Characterization of the First Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Andreas F WidmerDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. andreas.widmer@usb.ch.
Winfried V KernDivision of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Jan A RothDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Markus DettenkoferDepartment of Environmental Health Sciences and Hospital Infection Control, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Tim GoettingDepartment of Environmental Health Sciences and Hospital Infection Control, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Hartmut BertzDivision of Hematology, Oncology, and Stem Cell Transplantation, Department of Medicine I, University Hospital and Medical Center, Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Christian TheilackerDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.ORCID http://orcid.org/0000-0003-0821-9202
Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS)
University of Freiburg · DEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe length of neutropenia has a significant impact on the incidence of bloodstream infection (BSI) in cancer patients, but limited information is available about the pathogen distribution in late BSI.

methodsBetween 2002 and 2014, BSI episodes in patients with neutropenia receiving chemotherapy for hematologic malignancies were prospectively identified by multicenter, active surveillance in Germany, Switzerland and Austria. The incidence of first BSI episodes, their microbiology and time to BSI onset during the first episode of neutropenia of 15,988 patients are described.

resultsThe incidence rate of BSI episodes was 14.7, 8.7, and 4.7 per 1000 patient-days in the first, second, and third week of neutropenia, respectively. BSI developed after a median of 5 days of neutropenia (interquartile range [IQR] 3-10 days). The medium duration of neutropenia to BSI onset was 4 days in Escherichia coli (IQR 3-7 days), Klebsiella spp. (2-8 days), and Staphylococcus aureus (3-6 days). In contrast, BSI due to Enterococcus faecium occurred after a median of 9 days (IQR 6-14 days; p < 0.001 vs. other BSI). Late onset of BSI (occurring after the first week of neutropenia) was also observed for Stenotrophomonas maltophilia (12 days, IQR 7-17 days; p < 0.001), and non-albicans Candida spp. (13 days, IQR 8-19 days; p < 0.001).

conclusionsOver the course of neutropenia, the proportion of difficult to treat pathogens such as E. faecium, S. maltophilia, and Candida spp. increased. Among other factors, prior duration of neutropenia may help to guide empiric antimicrobial treatment in febrile neutropenia.

Indexed as

AdultAnti-Bacterial AgentsAntineoplastic AgentsAustriaBacteremiaCross InfectionEpidemiological MonitoringFemaleGermanyGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHematologic NeoplasmsHumansIncidenceMaleMiddle AgedAnti-Bacterial AgentsAntineoplastic AgentsBacteremiaBloodstream infectionHematologic malignancyNeutropenia

Identifiers

PMID31187401
OpenAlexW2950723297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.